價格 | ¥177 | ¥393 | ¥643 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-02 |
中文名稱:阿替美唑 | 英文名稱:Atipamezole |
CAS:104054-27-5 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.76% | 產(chǎn)品類別: 抑制劑 |
貨號: T6766 |
名稱 | Atipamezole |
描述 | Atipamezole (Antisedan) is a synthetic α2 adrenergic receptor antagonist. It has also been researched in humans as a potential anti-Parkinsonian drug. |
體外活性 | The affinity of atipamezole for α2-adrenoceptors and its α2/α1 selectivity ratio are considerably higher than yohimbine. Atipamezole is not selective for subtypes of α2-adrenoceptors. It has negligible affinity for 5-HT1, 5-HT2 and I2 bindings sites[1]. |
體內(nèi)活性 | Atipamezole is well tolerated in rodents. The cardiovascular effects of atipamezole (0.01–1 mg/kg, i.v.) are rather modest in anesthetized, normotensive rats. Atipamezole is commonly used by veterinarians to awaken animals from sedation or anesthesia. Atipamezole increases sexual activity in rats and monkeys. In animals with sustained nociception, atipamezole increases pain-related responses by blocking the noradrenergic feedback inhibition of pain. Atipamezole at low doses has beneficial effects on alertness, selective attention, planning, learning, and recall in experimental animals while not necessarily on short-term working memory[1]. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 39 mg/mL (183.7 mM) Ethanol : 39 mg/mL (183.7 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) |
關(guān)鍵字 | Adrenergic Receptor | Beta Receptor | MPV1248 | MPV-1248 | Inhibitor | inhibit | Atipamezole |
相關(guān)產(chǎn)品 | Buflomedil hydrochloride | Phenylephrine hydrochloride | Mirtazapine | Amitriptyline hydrochloride | Olanzapine | Trazodone hydrochloride | Mianserin hydrochloride | Gemfibrozil | Doxepin hydrochloride | Octopamine hydrochloride | Isoprenaline hydrochloride | Dexmedetomidine hydrochloride |
相關(guān)庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | FDA上市及藥典收錄分子庫 | GPCR靶點分子庫 | 膜蛋白靶向化合物庫 | 神經(jīng)退行性疾病化合物庫 | 藥物功能重定位化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.2651萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 化學試劑,生物活性小分子 | 經(jīng)營模式 | 貿(mào)易,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP1年
|
陜西格列弗生物科技研究有限責任公司
|
2025-02-10 | |
¥11 |
VIP2年
|
廣州旺晟生物科技有限公司
|
2025-02-08 | |
¥203.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-01-20 | |
¥205.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 | |
詢價 |
杭州柯萊生物醫(yī)藥科技有限公司
|
2024-09-06 | ||
詢價 |
VIP2年
|
陜西西化化學工業(yè)有限公司
|
2024-07-24 | |
詢價 |
VIP13年
|
隨州市紅旗化工有限公司
|
2023-07-05 | |
¥11 |
武漢鑫佳靈生物科技有限公司原料銷售部
|
2021-01-08 |